Successful treatment with ustekinumab in CARD14-associated papulosquamous eruption in a Brazilian child

Dermatol Ther. 2022 Dec;35(12):e15939. doi: 10.1111/dth.15939. Epub 2022 Oct 26.

Abstract

CARD14-associated papulosquamous eruption (CAPE) was proposed in 2018 to describe the clinical features of psoriasis and pityriasis rubra pilaris with CARD 14 mutations. We report a 5-month-old female infant who developed CAPE-associated erythroderma. Although she did not respond to conventional therapies, she responded well to ustekinumab treatment at the age of 4 years.

Keywords: genetic diseases/genodermatoses; inflammatory disorders; psoriasis.

Publication types

  • Case Reports

MeSH terms

  • CARD Signaling Adaptor Proteins / genetics
  • Child, Preschool
  • Dermatitis, Exfoliative* / diagnosis
  • Dermatitis, Exfoliative* / drug therapy
  • Exanthema* / drug therapy
  • Female
  • Guanylate Cyclase / genetics
  • Guanylate Cyclase / therapeutic use
  • Humans
  • Infant
  • Membrane Proteins / therapeutic use
  • Pityriasis Rubra Pilaris* / diagnosis
  • Pityriasis Rubra Pilaris* / drug therapy
  • Psoriasis* / diagnosis
  • Psoriasis* / drug therapy
  • Psoriasis* / genetics
  • Ustekinumab / therapeutic use

Substances

  • CARD Signaling Adaptor Proteins
  • CARD14 protein, human
  • Guanylate Cyclase
  • Membrane Proteins
  • Ustekinumab